LONG MINI-FUTURE - NOVO-NORDISK B | Delayed Deutsche Boerse AG 18:43:36 19/06/2024 BST | ||
| 21.88 EUR | +0.88% |
|
| Current month | +6.58% | ||
| 1 month | +9.88% |
Comparison chart between the derivative product and it's underlying value
End-of-day quotes
Chart
NOVO NORDISK A/S
Latest news about NOVO NORDISK A/S
| Date | Price | Change |
|---|---|---|
| 19/06/24 | 21.88 | +0.88% |
| 18/06/24 | 21.69 | -1.36% |
| 17/06/24 | 21.99 | -1.52% |
| 14/06/24 | 22.33 | +1.59% |
| 13/06/24 | 21.98 | -0.36% |
Delayed Quote Deutsche Boerse AG
Last update June 19, 2024 at 06:43 pm
More quotesStatic data
| Product type | Knock-Out with Stop Loss |
|---|---|
| Buy / Sell | CALL |
| Underlying | NOVO NORDISK A/S |
| Issuer | 
Vontobel
|
| WKN | VF80NG |
| ISIN | DE000VF80NG2 |
| Date issued | 08/08/2019 |
| Strike | 162.8 kr |
| Maturity | Unlimited |
| Parity | 5 : 1 |
| Emission price | 0.32 € |
| Emission volume | N/A |
| Settlement | cash |
| Currency | EUR |
Technical Indicators
| Highest since issue | 22.33 € |
|---|---|
| Lowest since issue | 0.28 € |
| Spread | 0.14 € |
| Spread % | 0.63% |
Company Profile
Novo Nordisk A/S specializes in the design, manufacture and marketing of pharmaceutical products. Net sales break down by family of products as follows:
- diabetes and obesity treatment products (92.6%);
- rare disease treatment products (7.4%): intended for the treatment of haemophilia, blood disorders, hormonal disorders, etc.
Net sales are distributed geographically as follows: Europe/Middle East/Africa (21.9%), the United States (54.9%), North America (3.9%), China (7.2%) and other (12.1%).
Sector
-
Consensus: Novo Nordisk A/S
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
26
Last Close Price
981.2
DKK
Average target price
934.3
DKK
Spread / Average Target
-4.78%
- Stock Market
- Certificates
- Certificat
